Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 176

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 176
---
 45.
The average age of people when diagnosed is about 70.

Lung cancer is by far the
leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths. Each year, more people die of lung cancer
than of colon, breast, and prostate cancers combined.

Overall, the chance that
a man will develop lung cancer in his lifetime is about 1 in 16; for a woman, the risk is about 1 in 17. These numbers include both people
who smoke and those who don’t smoke. For people who smoke, the risk is much higher, while for those who don’t, the risk is
lower.

| ● | Black                                                                                      
 men are about 12% more likely to develop lung cancer than White men. The rate is about 16% 
 lower in Black women than in White women.                                                  |

| ● | Black                                                                                       
 and White women have lower rates than men, but the gap is closing. The lung cancer rate has 
 been dropping among men over the past few decades, but only for about the past decade in    
 women.                                                                                      |

| ● | Despite                                                                              
 their overall risk of lung cancer being higher, Black men are less likely to develop 
 SCLC than White men.                                                                 |

Statistics on survival in
people with lung cancer vary depending on the type of lung cancer, the stage (extent) of the cancer when it is diagnosed, and other factors.

5-year relative survival rates for non-small cell lung cancer

These numbers are based on people diagnosed with NSCLC between 2012 and 2018.

| SEER                     
 stage                    |     | 5-year                 
 relative survival rate |
| Localized                |     | 65%                    |
| Regional                 |     | 37%                    |
| Distant                  |     | 9%                     |
| All SEER stages combined |     | 28%                    |

Our therapeutic approach and development program

We anticipate the design
of the clinical development program for CER-1236 to enable our evaluation of its therapeutic utility in treating both hematologic and
solid tumors, as the capacity of a single therapeutic construct to provide clinical benefit across this diversity of tumor types would
represent a significant advance in cancer immunotherapy. Due to the therapy’s novel mechanism of action, engaging both the innate
and the adaptive immune response, and the broad expression profile of PS on a variety of hematologic and solid tumors, we intend to employ